TAVR by Edwards provides lasting clinical benefits1,2
TAVR by Edwards at 1 year in low-risk patients1
99%
experienced freedom from death, disabling stroke, and rehospitalization due to heart failure
93%
experienced freedom from a new pacemaker after receiving TAVR
SAPIEN 3 TAVR was studied in the PARTNER 3 Trial.1
The primary endpoints were all-cause death, stroke, and rehospitalization at 1 year, with multiple prespecified secondary endpoints in low-risk patients.1
SAPIEN 3 Transcatheter Heart Valve System and SAPIEN 3 Ultra TAVR involve serious risks, including death, stroke, major bleeding, and major vascular complications.
of recipients experienced successful post-TAVR coronary access4 (n=68)
Only TAVR by Edwards heart valves are approved for TAVR-in-TAVR procedures
For patients assessed at high risk for surgical valve replacement.
TAVR was proven superior to SAVR at 1 year—and equally as effective at 5 years1,2
At 5 years, TAVR demonstrated comparable results vs SAVR
The PARTNER 3 Trial, SAPIEN 3 TAVR was proven superior to surgery on the primary endpoint of all-cause death, all stroke, and re-hospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients.1
PARTNER 3 Trial 5-Year Results in low-risk patients – Low rates of cardiovascular mortality through five years (5.5% SAPIEN 3 TAVR to 5.1% SAVR). Low rates of all-cause mortality through five years (10.1% SAPIEN 3 TAVR vs. 8.2% with SAVR). Low rates of disabling stroke through five years (2.9% SAPIEN 3 TAVR to 2.7% SAVR). Low rates of stroke through five years (5.8% SAPIEN 3 TAVR vs. 6.4% SAVR). Lower rates of rehospitalization with SAPIEN 3 TAVR through five years (13.7% vs. 17.4%).2
SAPIEN 3 valves are designed with your patients' future in mind, offering a comprehensive approach to durability5
Over the past decade, TAVR has become the preferred treatment for patients with symptomatic severe aortic stenosis (sSAS). At 10 years, 98% of TAVR recipients did not require valvular reintervention.*6,8
*When accounting for death as a competing risk.
READY TO HAVE THE TAVR DISCUSSION WITH YOUR PATIENT?
Download the TAVR Info Kit, which contains details about the procedure.
References:1.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.2.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960.3.Nazif TM, Cahill TJ, Daniels D, et al. Real-world experience with the SAPIEN 3 Ultra transcatheter heart valve: a propensity-matched analysis from the United States. Circ Cardiovasc Interv. 2021;14(9):e010543.4.Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7):e008972.5.Rheude T, Blumenstein J, Möllmann H, Husser O. Spotlight on the SAPIEN 3 transcatheter heart valve. Med Devices (Auckl). 2018;11:353-360. Published 2018 Oct 1.6.Madhavan MV, Kodali SK, Thourani VH, et al. Outcomes of SAPIEN 3 transcatheter aortic valve replacement compared with surgical valve replacement in intermediate-risk patients. J Am Coll Cardiol. 2023;82(2):109-123.7.Flameng W, Hermans H, Verbeken E, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149(1):340-345.8.Baron SJ, Ryan MP, Chikermane SG, Thompson C, Clancy S, Gunnarsson CL. Long-term risk of reintervention after transcatheter aortic valve replacement. Am Heart J. 2024;267:44-51.
Patients and/or clinicians quoted on this website have received compensation from Edwards Lifesciences.
You are about to leave TreatHeartValveFailure.com
By clicking this link, you understand that the website that you will be taken to is not controlled or endorsed by Edwards Lifesciences (“Edwards”), and Edwards does not own, control or influence the content found on the third-party website. You also understand that Edwards does not own or control any first- or third-party advertising, marketing or analytics technologies that may be on the third-party website.
TAVR by Edwards is now the FIRST and ONLY TAVR to be approved for the treatment of both symptomatic and asymptomatic patients with severe aortic stenosis, also known as heart valve failure.
